SG11201605099YA - Injectable agent and depot formation method - Google Patents

Injectable agent and depot formation method

Info

Publication number
SG11201605099YA
SG11201605099YA SG11201605099YA SG11201605099YA SG11201605099YA SG 11201605099Y A SG11201605099Y A SG 11201605099YA SG 11201605099Y A SG11201605099Y A SG 11201605099YA SG 11201605099Y A SG11201605099Y A SG 11201605099YA SG 11201605099Y A SG11201605099Y A SG 11201605099YA
Authority
SG
Singapore
Prior art keywords
formation method
injectable agent
depot formation
depot
injectable
Prior art date
Application number
SG11201605099YA
Inventor
Kenji Oki
Kazuhito Yamada
Tatsuya Miyazaki
Komei Okabe
Sayo Habashita
Hiroshi Enomoto
Kenta Yoshii
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of SG11201605099YA publication Critical patent/SG11201605099YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Colloid Chemistry (AREA)
SG11201605099YA 2013-12-25 2014-12-25 Injectable agent and depot formation method SG11201605099YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013266567 2013-12-25
PCT/JP2014/084289 WO2015099029A1 (en) 2013-12-25 2014-12-25 Injectable agent and depot formation method

Publications (1)

Publication Number Publication Date
SG11201605099YA true SG11201605099YA (en) 2016-07-28

Family

ID=53478876

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605099YA SG11201605099YA (en) 2013-12-25 2014-12-25 Injectable agent and depot formation method

Country Status (12)

Country Link
US (1) US20160303240A1 (en)
EP (1) EP3088003A4 (en)
JP (1) JP6423263B2 (en)
KR (1) KR20160101905A (en)
CN (1) CN105792849A (en)
CA (1) CA2933150A1 (en)
EA (1) EA201691132A1 (en)
GE (1) GEP20186930B (en)
PH (1) PH12016501256A1 (en)
SG (1) SG11201605099YA (en)
TW (1) TW201609145A (en)
WO (1) WO2015099029A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6762158B2 (en) * 2015-07-28 2020-09-30 日本化薬株式会社 Pharmaceutical composition containing rapamycin or a derivative thereof
EP3329916A4 (en) * 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition including rapamycin or derivative thereof, and production method therefor
JP6854639B2 (en) * 2016-01-06 2021-04-07 日本化薬株式会社 Pharmaceutical composition containing rapamycin derivative and method for producing the same
KR20180036580A (en) 2016-09-30 2018-04-09 주식회사 유스바이오팜 Composition for prevention or treatment of inflammatory skin diseases or severe pruritus comprising the aqueous solubilized ursodeoxycholic acid
KR102252450B1 (en) * 2017-02-09 2021-05-14 주식회사 아미코젠파마 Composition for prevention or treatment of visual disorders comprising ursodeoxycholic acid
CN115414324A (en) * 2021-05-31 2022-12-02 中国科学院过程工程研究所 Emulsion carrying local anesthetic and preparation method thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1336410A4 (en) * 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd Protein injection preparations
JP2006503014A (en) * 2002-08-20 2006-01-26 プロテミックス コーポレイション リミティド Dosage forms and related treatments
CA2508303C (en) * 2002-12-04 2012-10-23 Santen Pharmaceutical Co., Ltd. Drug delivery system using subconjunctival depot
JP4496406B2 (en) 2003-03-07 2010-07-07 参天製薬株式会社 Novel compound having 4-pyridylalkylthio group as a substituent
JP4626353B2 (en) 2004-02-17 2011-02-09 参天製薬株式会社 Novel cyclic compound having a 4-pyridylalkylthio group having a substituted or unsubstituted amino group introduced
EA012205B1 (en) * 2004-05-17 2009-08-28 Арес Трейдинг С.А. Hydrogel interferon formulations
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
JP4585978B2 (en) 2005-03-03 2010-11-24 参天製薬株式会社 Novel cyclic compounds having a quinolylalkylthio group
JP4834441B2 (en) 2005-03-31 2011-12-14 参天製薬株式会社 Novel cyclic compounds having pyrimidinylalkylthio groups
JP4825636B2 (en) 2005-09-14 2011-11-30 参天製薬株式会社 Novel 1,2-dihydroquinoline derivatives having glucocorticoid receptor binding activity
JP5217136B2 (en) * 2005-10-18 2013-06-19 大正製薬株式会社 Semi-solid formulation for rectal, urethral and vaginal applications.
US7700618B2 (en) 2006-03-06 2010-04-20 Pfizer Inc Sulfonyl benzimidazole derivatives
JP5054996B2 (en) 2006-03-14 2012-10-24 参天製薬株式会社 Novel 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity
KR20090086539A (en) 2006-11-14 2009-08-13 산텐 세이야꾸 가부시키가이샤 Novel 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents
JP2008266295A (en) 2007-01-29 2008-11-06 Santen Pharmaceut Co Ltd New thiadiazole derivative having kinase inhibitory activity
CN101679317B (en) 2007-05-29 2012-10-31 参天制药株式会社 Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor binding activity
JP2009084274A (en) 2007-09-13 2009-04-23 Santen Pharmaceut Co Ltd New 1,3,3-trimethyl-7-phenyl-3,4-dihydro-1h-quinoxalin-2-one derivative
JP2010132587A (en) * 2008-12-03 2010-06-17 Teika Seiyaku Kk Ophthalmic agent
CN102471273B (en) 2009-07-17 2014-07-16 参天制药株式会社 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof
RU2556340C2 (en) * 2009-07-31 2015-07-10 Санофи-Авентис Дойчланд Гмбх Long-acting insulin composition
JP5713791B2 (en) * 2010-05-12 2015-05-07 テイカ製薬株式会社 Ophthalmic agent
CA2809460C (en) * 2010-09-03 2018-12-11 Novagali Pharma Sa A water-in-oil type emulsion for treating a disease of the eye
US9469630B2 (en) * 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
IT1404145B1 (en) * 2010-12-27 2013-11-15 Altergon Sa COMPOSITIONS OF HYALURONIC ACID STABILIZED TOWARDS THE DEGRADATION OF HEAT OR ENZYMES
JP5931449B2 (en) * 2012-01-11 2016-06-08 日東電工株式会社 Pharmaceutical composition and method for producing the same
CN102626381B (en) * 2012-04-19 2013-05-29 海南灵康制药有限公司 Vesicular phospholipid gel injection of latamoxef sodium

Also Published As

Publication number Publication date
JP2015143217A (en) 2015-08-06
US20160303240A1 (en) 2016-10-20
JP6423263B2 (en) 2018-11-14
TW201609145A (en) 2016-03-16
GEP20186930B (en) 2018-12-10
CA2933150A1 (en) 2015-07-02
KR20160101905A (en) 2016-08-26
EP3088003A1 (en) 2016-11-02
WO2015099029A1 (en) 2015-07-02
PH12016501256A1 (en) 2016-08-15
CN105792849A (en) 2016-07-20
EA201691132A1 (en) 2016-11-30
EP3088003A4 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
GB2518057B (en) Tracer and method
HUE053410T2 (en) Application method and application facility
ZA201403959B (en) Mine wifi and method
EP2952097A4 (en) Pest-control composition and pest-control method
GB201306633D0 (en) Biaising circuitry and method thereof
EP2952100A4 (en) Pest-control composition and pest-control method
HUE039729T2 (en) Variable-density composite articles and method
EP2970734A4 (en) Compositions and method for refrigeration
GB201305414D0 (en) Method and composition
EP2952099A4 (en) Pest-control composition and pest-control method
SG11201605099YA (en) Injectable agent and depot formation method
GB201300376D0 (en) Method and compound
AP2016009013A0 (en) Fairing and method
GB201313803D0 (en) Fungicidal composition and method
HK1224348A1 (en) Soil-volume reduction method
GB2584039B (en) Container assembly and method
GB201515529D0 (en) Injector and method
GB201415361D0 (en) Hosiery and method
GB201320359D0 (en) Assembly and method
GB201308285D0 (en) Method and document
HK1222609A1 (en) Gas barrier enhancing additives and methods
HUE035872T2 (en) Storage and storage method
EP3001617A4 (en) Entry adding method and switch
GB2522839B (en) Method and document
GB2519994B (en) Assemblies and methods